Investors on the hunt for a fast-growing dividends need look no further than Abbott Laboratories (ABT).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In December of last year, Abbott increased its dividend by 6.8% to $0.63 per share. It was the 54th year in a row that Abbott has increased its dividend. Since 2020, the dividend has grown by 70%, faster than just about any other dividend on offer.
Currently, ABT stock has a dividend yield of 2.42%, which is about double the average dividend yield among stocks listed in the benchmark S&P 500 index. Management at Abbott Labs continues to prioritize the dividend and rewarding its shareholders.
ABT Stock Performance
The rapid dividend growth at Abbott comes as the company’s stock has struggled. Over the last five years, the company’s share price has declined 15%. So far in 2026, the shares are down 16%. The main reason for the decline has been its baby-formula business.
Abbott has increasingly raised the price of its baby formula as manufacturing costs have risen and due to tariffs, hurting sales in the process. Most recently, Abbott reported that its nutrition sales were $1.9 billion, which was below analyst expectations. However, overall Abbott’s financial results have been strong and the company’s main business making medical devices remains solid.
While shareholders wait for ABT stock to recover, they can comfort themselves with the growing dividend.
Is ABT Stock a Buy?
Abbott Laboratories stock has a consensus Strong Buy rating among 15 analysts. That rating is based on 14 Buy and one Hold recommendations issued in the last three months. The average ABT price target of $137.14 implies 31% upside from current levels.
